The 30th European Hematology Association (EHA) Congress (EHA 2025), held in Milan, Italy, from June 12-15, 2025, continued ...

Key challenges include logistical hurdles, such as the need for specialized training and infrastructure, and financial ...

The waveLINE-003 trial demonstrates the efficacy of zilovertamab vedotin combined with standard therapy, with manageable safety profiles in difficult-to-treat DLBCL patients. ADCs provide logistical ...

Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

Bristol Myers Squibb reinforces its haematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Haematology (ASH) Annual Meeting.

Antibody treatments for cancer and other diseases are typically delivered intravenously, because of the large volumes that are needed per dose. This means the patient has to go to a hospital for every ...

In a randomized clinical trial, vixarelimab demonstrates dose-dependent, long-term safety and efficacy in patients with ...

Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

At the American Society of Hematology (ASH) Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 clinical trial were presented.

On the 21st, the Ministry of Health and Welfare said the 11th Advanced Regenerative Medicine and Advanced Biopharmaceuticals Review Committee of 2025 ruled three of eight clinical studies as ...